Literature DB >> 32584170

Identification of the Novel Target Genes for Osteosarcoma Therapy Based on Comprehensive Bioinformatic Analysis.

Xi Zhou1, Yu Fan1, Weiliang Ye2, Binghan Jia2, Yuemei Yang2, Yong Liu1.   

Abstract

Osteosarcoma is one of the most common primary malignant tumors of the bone and tends to develop in teenage years. Although multitreatments for the diagnosis and therapy of osteosarcoma have been developed, there are still needs of new methods to prevent and treat the osteosarcoma. Here, we performed bioinformatic analysis to screen for the key genes, molecules, and pathways involved in osteosarcoma survival. Four microarray data sets (GSE99671, GSE87624, GSE65071, and GSE28423), which include data from human bone and osteosarcoma samples, were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed mRNAs and miRNAs were identified. Kyoto Encyclopedia of Genes and Genomes enriched pathways, miRNA-mRNA target, gene/disease relationship, and overall survival was elucidated using related websites and software according to bioinformatic analysis protocols. We found three critical genes miR-29c, blood vessel epicardial substance (BVES), and proteasome 20S subunit beta 2 (PSMB2) through the GEO database and predicting miRNA-mRNA target. Among these genes, BVES and PSMB2 presented a high expression level in osteosarcoma based on GSE99671 and GSE87624 data sets, while miR-29c showed a low expression level in osteosarcoma based on GSE65071 and GSE28423 data sets. Furthermore, we found that the high expression level of miR-29c and BVES associated with better prognosis, while highly expressed PSMB2 associated with poor prognosis. The abnormally expressed mRNAs and miRNAs, which were identified by integrated bioinformatic analysis, provided insights into the molecular mechanisms of osteosarcoma. Notably, we found three critical genes that could be used as novel therapeutic targets for preventing or diagnosing osteosarcoma. Finally, PSMB2 may be the target of miR-29c.

Entities:  

Keywords:  bioinformatic analysis; gene analysis; molecular mechanism; osteosarcoma; overall survival; therapeutic targets

Year:  2020        PMID: 32584170     DOI: 10.1089/dna.2020.5377

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

1.  PSMB2 knockdown suppressed proteasome activity and cell proliferation, promoted apoptosis, and blocked NRF1 activation in gastric cancer cells.

Authors:  Zimeng Liu; Changda Yu; Zhibing Chen; Chuanwen Zhao; Lin Ye; Chen Li
Journal:  Cytotechnology       Date:  2022-06-27       Impact factor: 2.040

2.  Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma.

Authors:  Jing-Yi Guo; Zuo-Qian Jing; Xue-Jie Li; Li-Yuan Liu
Journal:  Int J Med Sci       Date:  2022-05-01       Impact factor: 3.642

3.  Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective.

Authors:  Yanna Zhang; Xun Wang; Xiancheng Chen
Journal:  Aging (Albany NY)       Date:  2021-01-25       Impact factor: 5.682

4.  MicroRNA-376b-3p targets RGS1 mRNA to inhibit proliferation, metastasis, and apoptosis in osteosarcoma.

Authors:  Lei Zhang; Meng Yao; Weikang Ma; Yongqing Jiang; Wenbo Wang
Journal:  Ann Transl Med       Date:  2021-11

5.  Tumor suppressing role of serum-derived exosomal microRNA-15a in osteosarcoma cells through the GATA binding protein 2/murine double minute 2 axis and the p53 signaling pathway.

Authors:  Chunyu Wu; Zhigang Li; Guang Feng; Liqin Wang; Jingri Xie; Yang Jin; Long Wang; Songjiang Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Screening and Analysis of Biomarkers in the miRNA-mRNA Regulatory Network of Osteosarcoma.

Authors:  Gang Han; Quanyi Guo; Nan Li; Wenzhi Bi; Meng Xu; Jinpeng Jia
Journal:  J Healthc Eng       Date:  2022-03-15       Impact factor: 2.682

7.  Circ_0136666 aggravates osteosarcoma development through mediating miR-1244/CEP55 axis.

Authors:  Xiang Gao; Nanwei Xu; Kaisong Miao; Gao Huang; Yong Huang
Journal:  J Orthop Surg Res       Date:  2022-09-15       Impact factor: 2.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.